Tom van Hagen
Overview
Explore the profile of Tom van Hagen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
3
Citations
21
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tan A, McSweeney T, Sikotra N, Adler B, van Hagen T, Summers Q, et al.
Immunotherapy
. 2025 Feb;
17(2):103-111.
PMID: 39995195
Aim: We describe a single-center burden of admissions for irAE management and rechallenge feasibility. Methods: A retrospective single-center study of patients receiving immunotherapy between 2015-2018 assessing irAE and immunotherapy rechallenge...
2.
Chia J, Segelov E, Deng Y, Ho G, Wang W, Han S, et al.
Lancet Gastroenterol Hepatol
. 2025 Jan;
10(3):198-209.
PMID: 39824200
Background: Aspirin is a simple, globally available medication that has been shown to reduce the incidence of colorectal cancer. We aimed to evaluate the safety and efficacy of aspirin in...
3.
Halliday G, Junckerstorff R, Bentel J, Miles A, Jones D, Hovestadt V, et al.
J Clin Neurosci
. 2017 Oct;
47:163-167.
PMID: 28993028
Central nervous system primitive neuro-ectodermal tumors (CNS-PNETs), have recently been re-classified in the most recent 2016 WHO Classification into a standby catch all category, "CNS Embryonal Tumor, not otherwise specified"...
4.
George A, Kristeleit R, Rafii S, Michie C, Bowen R, Michalarea V, et al.
Eur J Cancer
. 2017 Mar;
76:52-59.
PMID: 28273485
Drug resistance to conventional anticancer therapies is almost inevitable in patients with advanced ovarian cancer (AOC), limiting their available treatment options. Novel phase I trial therapies within a dedicated drug...
5.
Han L, Karavasilis V, van Hagen T, Nicum S, Thomas K, Harrison M, et al.
Eur J Cancer
. 2010 Mar;
46(8):1359-64.
PMID: 20303743
Introduction: Confirmed doubling of CA125 value is one definition of progression in ovarian cancer patients. If asymptomatic, the management of these patients is unclear. To provide information which may assist...